The International Alpha Thalassemia Consortium, hosted by the UCSF Center for Maternal-Fetal Precision Medicine, brings together an interdisciplinary group of clinicians and scientists from around the world to focus expertise in hematology, maternal-fetal medicine, genetics, fetal therapy, and neonatology on alpha thalassemia major (ATM).
We gather quarterly in a virtual seminar to share advances, challenges, and best practices regarding clinical care for prenatal, pediatric, and adult patients diagnosed with ATM.
All are welcome.
Next Quarterly Seminar
November 2022 – Date & Time TBD
.
.
Past Seminars
August 23, 2022
Developing Gene Therapy Strategies to Treat Alpha Thalassemia
- Three-pronged approach to develop gene therapies to cure alpha thalassemia major ex vivo
- In-depth look at CRISPR/AAV6-mediated genome editing correction strategy
- Future directions that include the potential adaptation of successful ex vivo strategies for in utero and postnatal in vivo delivery
May 9, 2022
Perinatal Management and Postnatal Transplant for Alpha Thalassemia Major: A Case from Netherlands
.
.
February 22, 2022
Patient Registry for Alpha Thalassemia: Deeper Understanding of Disease Outcomes
- Patients registry demographics
- Outcomes in patients that pursued fetal therapy
- Silver linings: unintended outcomes from referring provider collaborations
November 30, 2021
Iron Overload and Chelation Management in Patients with Alpha Thalassemia Major
- Risk of iron overload and its related complications in alpha thalassemia patients
- Standard of care practices for iron overload monitoring
- Review the currently available options for iron chelation
August 17, 2021
Technical Aspects of In Utero Transfusions for Alpha Thalassemia Major
- How and when to initiate invasive diagnostics and transfusion therapy in fetuses suspected to have alpha thalassemia
- Technical aspects of determining how much to transfuse, the frequency of transfusions, and the role and technical considerations for fetal exchange transfusion
- Troubleshooting strategies for difficult cases such as fetuses requiring transfusion at early gestational ages
May 20, 2021
Allogeneic Hematopoietic Stem Cell Transplantation for Alpha Thalassemia Major
- current practices in hematopoietic stem cell transplantation for ATM, and upcoming advances that improve survival of babies with ATM
ATM Patient Registry & Clinical Trial
To refer a patient to the patient registry or clinical trial, please contact Billie.Lianoglou@ucsf.edu.
International Registry of Patients with Alpha Thalassemia (ATM Registry)
The aim of this registry is to prospectively and retrospectively collect data on patients who are diagnosed with alpha thalassemia major (ATM) and other alpha thalassemia mutations. Data collected will be used to:
- Understand the natural history of the disease
- Identify patient outcomes of therapies
- Improve clinical management of patients with ATM
- Improve medical decision making
- Improve quality of care
Phase 1 Clinical Trial: In Utero Hematopoietic Stem Cell Transplantation for Alpha Thalassemia Major
Clinical trial to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with ATM, performed at the time of in utero transfusion of red blood cells.
Learn more about this trial at the UCSF Fetal Treatment Center.